Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The effect of the CYP 2C19*2 polymorphism on stroke care.

Acta physiologica Hungarica - 1 Mar 2012

Nyírő G, Inczédy-Farkas G, Reményi V, Gál A, Pál Zs, Molnár Mária Judit

Abstract excerpt

Clopidogrel is an inhibitor of platelet-aggregation used in the prevention of secondary stroke. The molecule is activated by the cytochrome P450 2C19 (CYP2C19) enzyme. The frequent CYP2C19*2 point mutation causes loss of enzyme function, a decreased (heterozygous form) or blocked (homozygous form) formation of the active molecule. Thus, for a patient harboring a mutated allele, clopidogrel does not provide...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryl Hydrocarbon Hydroxylases
Share to Clopidogrel
Share to Cytochrome P-450 CYP2C19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hungary

Share to Pharmacogenetics

Share to Platelet Aggregation Inhibitors

Share to Stroke

Share to Ticlopidine

Source

Identifiers

PMID: 22425806
DOI: 10.1556/APhysiol.99.2012.1.4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The effect of the CYP 2C19*2 polymorphism on stroke care.PMID 22425806Read ↗

Pharmacogenetics of CYP2C19 genetic polymorphism on clopidogrel response in patients with ischemic stroke from Saudi ArabiaSemantic proximity Read ↗

Genetic variability in stroke patients: CYP2C19 polymorphisms unraveled.Semantic proximity Read ↗

CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China.Semantic proximity Read ↗

The role of CYP2C19 genotyping to guide antiplatelet therapy following ischemic stroke or transient ischemic attack.Semantic proximity Read ↗

Prevalence of CYP2C9 and CYP2C19 variants and the impact on clopidogrel efficacy in patients having CYPC19*2 variant.Semantic proximity Read ↗

Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Clopidogrel preventive effect based on cytochrome P450 2C19 genotype in ischaemic stroke: protocol for multicentre observational study.Semantic proximity Read ↗

Cytochrome P450 2C19 polymorphism and antiplatelet therapy. Who should really be genotyped?Semantic proximity Read ↗

Association with CYP2C19 polymorphisms and Clopidogrel in treatment of elderly stroke patients.Semantic proximity Read ↗

The Impact of CYP2C19 Loss-of-Function Polymorphisms, Clinical, and Demographic Variables on Platelet Response to Clopidogrel Evaluated Using Impedance Aggregometry.Semantic proximity Read ↗

Genotyping genetic variants of CYP2C19 for precision antiplatelet dosing: state of the art and future perspectives.Semantic proximity Read ↗

Investigating CYP2C19 loss-of-function allele statuses and their association with stroke of different etiologies in a Taiwanese populationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.